325 results
8-K
EX-99.1
INVA
Innoviva Inc
13 May 24
Corporate Presentation May 2024
9:27am
treatments that do not act directly on the heart due to safety concerns 70% 23% Increase in Mean Arterial Pressure Response 1 In a pivotal trial, GIAPREZA
8-K
EX-99.1
INVA
Innoviva Inc
6 Nov 23
Regulation FD Disclosure
8:30am
) in participants who had a positive culture for gonorrhea at baseline. Secondary analyses were microbiological cure at rectal or pharyngeal sites and safety … cure at rectal or pharyngeal sites at TOC (day 6 “ 2); safety Oral dose zoliflodacin (3g) Ceftriaxone IM injection (500mg) + oral azithromycin (1g
8-K
EX-99.1
ilrv03w74g rhoy
1 Nov 23
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:30pm
8-K
EX-99.1
3jiy bh7utb
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99.1
6v8i78ki7rcgf1
9 Nov 22
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:17pm
8-K
EX-99.1
64ko5
23 Aug 22
Other Events
4:08pm
8-K
EX-10.1
57c2hse
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-2.1
bku7169z7 0j1z507m48
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-2.1
zt6l3h 1gx1efqaibn
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am
425
1xo0l2jqla
11 Jul 22
Business combination disclosure
7:38am
SC TO-C
EX-2.1
nfmnz
23 May 22
Information about tender offer
8:53pm
8-K
EX-2.1
vjulz
23 May 22
Tender and Support Agreement
8:51pm